Predictive Oncology (NASDAQ:POAI – Get Free Report) and Tempus AI (NASDAQ:TEM – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.
Institutional and Insider Ownership
9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 24.2% of Tempus AI shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 26.3% of Tempus AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Predictive Oncology and Tempus AI, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Predictive Oncology | 1 | 0 | 0 | 0 | 1.00 |
| Tempus AI | 1 | 7 | 7 | 0 | 2.40 |
Risk & Volatility
Predictive Oncology has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Tempus AI has a beta of 4.99, suggesting that its share price is 399% more volatile than the S&P 500.
Earnings and Valuation
This table compares Predictive Oncology and Tempus AI”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Predictive Oncology | $1.66 million | 11.17 | -$12.66 million | ($13.50) | -0.41 |
| Tempus AI | $1.11 billion | 10.71 | -$705.81 million | ($1.19) | -55.93 |
Predictive Oncology has higher earnings, but lower revenue than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Predictive Oncology and Tempus AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Predictive Oncology | -5,065.23% | -732.73% | -235.55% |
| Tempus AI | -18.45% | -73.21% | -13.78% |
Summary
Tempus AI beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.
About Predictive Oncology
Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.
About Tempus AI
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.
Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
